<DOC>
	<DOCNO>NCT00673673</DOCNO>
	<brief_summary>This Phase II open-label study determine anti-tumor efficacy tolerability FOLFOX combination bevacizumab ( Avastin ( TM ) ) patient metastatic unresectable gastroesophageal gastric adenocarcinoma . Our primary objective determine time progression patient treat FOLFOX combination bevacizumab .</brief_summary>
	<brief_title>FOLFOX With Bevacizumab Metastatic Unresectable Gastroesophageal Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologically cytologically document recurrent , metastatic unresectable gastroesophageal ( Siewert type I , II , III ) gastric adenocarcinoma measurable assessable nonmeasurable disease ( RECIST criterion ) . If recurrent metastatic disease histologically confirm , documentation second radiographic procedure ( i.e. , PET scan MRI addition CT scan ) require . If imaging procedure confirm recurrent metastatic disease , biopsy confirmation require 12 month since completion prior neoadjuvant adjuvant therapy ( chemotherapy radiotherapy ) potentially resectable gastroesophageal gastric adenocarcinoma . &gt; 4 week since major surgery . ECOG Performance Status : 01 Life expectancy &gt; 12 week Laboratory parameter follow : absolute neutrophil count ≥1,500/uL , platelet count ≥100,000/uL , hemoglobin ≥9 g , /dL , creatinine &lt; 1.5 X ULN estimate GFR &gt; 30 ml's/min , urinalysis &lt; 2+ protein , baseline proteinuria &lt; 1000 mg/d urine protein/creatinine ratio &lt; 1 , bilirubin &lt; 2 X ULN , PT ( INR ) &lt; 1.5 patient anticoagulation , negative pregnancy test woman childbearing age Hypertension must well control ( &lt; 160/90 ) Paraffin block slide must available Patients fulldose anticoagulant must stable dose warfarin inrange INR stable dose low molecular weight heparin . prior treatment recurrent , metastatic , unresectable gastroesophageal gastric adenocarcinoma concurrent anticancer therapy malignancy within past three year except basal cell carcinoma skin , cervical carcinoma situ , nonmetastatic prostate cancer know central nervous system metastases carcinomatous meningitis . interstitial pneumonia extensive symptomatic interstitial fibrosis lung . &gt; grade 2 sensory peripheral neuropathy . uncontrolled seizure disorder , active neurological disease , know CNS disease . significant cardiac disease , include follow : unstable angina , New York Heart Association class IIIV congestive heart failure , myocardial infarction within six month prior study enrollment . history hypertensive crisis hypertensive encephalopathy abdominal fistula , gastrointestinal bleeding , intraabdominal abscess within 6 month prior study enrollment . core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior study enrollment . major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study enrollment anticipation need major surgical procedure course study . recent arterial thrombotic event include stroke TIA within 6 month prior study enrollment . serious nonhealing wound , ulcer bone fracture . active bleed pathological condition carry high risk bleeding ( e.g. , tumor involve major vessel know varix ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>